ADMA
ADMA Biologics, Inc.
ADMA has slightly lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has a slight edge over ADMA overall, supported by stronger fundamentals and stronger modeled upside.
ADMA Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Strong | |
| Strong |
ADMA's profitability, cash flow and balance sheet are currently strong, and its revenue is stable.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
ADMA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 14x | $10.76 | -19% |
| Forward | 16x | $13.24 | — |
| Current | 17x | $13.24 | — |
| Fair | 21x | $16.22 | +23% |
| Expensive | 66x | $50.55 | +282% |
Historical ranges are pointers, not guarantees.
ADMA's PE is in its cheap range at 17x. If earnings grow as analysts expect, today's price would be 16x next year's earnings.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over ADMA in the historical PE scenario, which offers more potential upside but is not a forecast.
ADMA Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for ADMA, with profitability improving.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
ADMA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.81 | +5.6% |
| Q3 2026 | $0.77 | -9.4% |
| Q2 2026 | $0.70 | -18% |
| Q1 2026 | $0.68 | -19% |
| Q4 2025 | $0.60 | -26% |
| Q3 2025 | $0.85 | +204% |
| Q2 2025 | $0.85 | +507% |
| Q1 2025 | $0.84 | +$0.86 |
| Q4 2024 | $0.81 | +$0.94 |
ADMA earned $0.77 per share over the past year, down 9.4% from the year before.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
ADMA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $141.1M | +5.1% |
| Q2 2026 | $124.4M | +2% |
| Q1 2026 | $114.5M | -0.3% |
| Q4 2025 | $139.2M | +18% |
| Q3 2025 | $134.2M | +12% |
| Q2 2025 | $122M | +14% |
| Q1 2025 | $114.8M | +40% |
| Q4 2024 | $117.5M | +59% |
ADMA's revenue is growing: $141M last quarter, up 5.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 48% | +10 points |
| Q2 2026 | 42% | +7.1 points |
| Q1 2026 | 51% | +21 points |
| Q4 2025 | 45% | +13 points |
| Q3 2025 | 38% | +4.9 points |
| Q2 2025 | 35% | -1.5 points |
| Q1 2025 | 30% | +3.7 points |
| Q4 2024 | 33% | +13 points |
ADMA has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over ADMA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
ADMA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $15.4M | +$16.4M |
| Q2 2026 | $27.3M | +46% |
| Q1 2026 | $55.7M | +$80.1M |
| Q4 2025 | $34.6M | -27% |
| Q3 2025 | -$1.1M | -104% |
| Q2 2025 | $18.7M | -57% |
| Q1 2025 | -$24.4M | -$19.8M |
| Q4 2024 | $47.5M | +189% |
ADMA has burned cash in most quarters: $133M over the past year, about three times what it generated the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over ADMA on cash flow, with more consistent year-over-year improvement.
ADMA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -2% | -4.5M shares |
| 1 year | -7.7% | -18.8M shares |
| 3 years | -3.4% | -7.9M shares |
| 5 years | +77% | +98.4M shares |
| Available history | +206% | +152M shares |
ADMA has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $25.1M |
| Q2 2026 | $25.1M |
| Q1 2026 | $130.2M |
| Q4 2025 | $8.9M |
ADMA spent $189M buying back its own shares over the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ADMA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.3x | Very low |
| Q2 2026 | 0.3x | Very low |
| Q1 2026 | 0.3x | Very low |
| Q4 2025 | -0.1x | Net Cash |
| Q3 2025 | 0.1x | Very low |
| Q2 2025 | -0.6x | Net Cash |
| Q1 2025 | -0.5x | Net Cash |
| Q4 2024 | -0.7x | Net Cash |
ADMA's net debt is less than a year of its operating earnings (EBITDA).
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over ADMA on leverage, with a lower net debt burden relative to earnings.
ADMA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 69.1 | Neutral |
| Stochastic | 85.4 | Overbought |
ADMA's weekly RSI is 69 (neutral) and its Stochastic is 85 (overbought).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
ADMA PE vs Healthcare Sector
| Metric | ADMA | Sector median | Relative |
|---|---|---|---|
| PE | 17x | 26x | 34% below |
| PE % | 28 | 29 | 1 pt below |
ADMA is trading at 17x earnings, a 34% discount to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over ADMA on valuation relative to its sector.
ADMA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.0 | 20% above |
| 20 week MA | $9.91 | 34% above |
| 50 week MA | $12.0 | 10% above |
| 100 week MA | $14.9 | 11% below |
| 200 week MA | $11.4 | 17% above |
ADMA's trend is mixed: it's above four of its five weekly moving averages, and 17% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over ADMA on trend strength, trading above more of its moving averages.
ADMA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $3.95 | $2.15 | -46% |
| 2021 | $2.15 | $1.27 | -41% |
| 2022 | $1.27 | $3.65 | +187% |
| 2023 | $3.65 | $4.52 | +24% |
| 2024 | $4.52 | $17.5 | +286% |
| 2025 | $17.5 | $19.3 | +10% |
| 2026 YTD | $19.3 | $13.2 | -31% |
ADMA's yearly returns have swung widely, from +286% in 2024 to −46% in 2020. It's down 31% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over ADMA on returns for 2026, with the stronger performance.